a Department of Pathology , Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Expert Rev Proteomics. 2019 Feb;16(2):93-103. doi: 10.1080/14789450.2019.1559062. Epub 2018 Dec 24.
Cancer is often diagnosed at late stages when the chance of cure is relatively low and although research initiatives in oncology discover many potential cancer biomarkers, few transition to clinical applications. This review addresses the current landscape of cancer biomarker discovery and translation with a focus on proteomics and beyond. Areas covered: The review examines proteomic and genomic techniques for cancer biomarker detection and outlines advantages and challenges of integrating multiple omics approaches to achieve optimal sensitivity and address tumor heterogeneity. This discussion is based on a systematic literature review and direct participation in translational studies. Expert commentary: Identifying aggressive cancers early on requires improved sensitivity and implementation of biomarkers representative of tumor heterogeneity. During the last decade of genomic and proteomic research, significant advancements have been made in next generation sequencing and mass spectrometry techniques. This in turn has led to a dramatic increase in identification of potential genomic and proteomic cancer biomarkers. However, limited successes have been shown with translation of these discoveries into clinical practice. We believe that the integration of these omics approaches is the most promising molecular tool for comprehensive cancer evaluation, early detection and transition to Precision Medicine in oncology.
癌症通常在晚期被诊断，此时治愈的机会相对较低。尽管肿瘤学的研究计划发现了许多潜在的癌症生物标志物，但很少有能转化为临床应用。本综述探讨了癌症生物标志物发现和转化的现状，重点关注蛋白质组学及其他领域。
本综述检查了用于癌症生物标志物检测的蛋白质组学和基因组学技术，并概述了整合多种组学方法以实现最佳灵敏度和解决肿瘤异质性的优势和挑战。这一讨论基于系统文献综述和直接参与转化研究。
早期发现侵袭性癌症需要提高灵敏度并采用代表肿瘤异质性的生物标志物。在过去十年的基因组学和蛋白质组学研究中，下一代测序和质谱技术取得了重大进展。这反过来又导致潜在的基因组和蛋白质组癌症生物标志物的数量急剧增加。然而，这些发现转化为临床实践的成功有限。我们相信，这些组学方法的整合是全面癌症评估、早期检测和向肿瘤学精准医学过渡的最有前途的分子工具。
